Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Tuberculosis, Multidrug-Resistant

• Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
• Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
• A Phase 1, Drug-Drug Interaction Study to Evaluate Safety, Tolerability, and Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adults
• A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
• A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
• A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB
• Linezolid Dosing Strategies in Drug-Resistant TB
• Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
• Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
• Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
• Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
• A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid
• Novel Triple-dose Tuberculosis Retreatment Regimen
• Economic Evaluation of New MDR TB Regimens
• A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant (DR-TB) Pulmonary TB Volunteers (PaSEM)
• PRACTECAL-PKPD Sub Study
• Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
• Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
• Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
• Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
• The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB
• Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
• NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB
• Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells
• Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
• Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
• The Individualized M(X) Drug-resistant TB Treatment Strategy Study
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB
• Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis
• Improving the Management of Drug Resistant Tuberculosis in the UK
• Evaluating Newly Approved Drugs for Multidrug-resistant TB
• Treatment Shortening of MDR-TB Using Existing and New Drugs
• FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis
• Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
• A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
• Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic
• Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
• An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
• The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
• An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
• Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB
• A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis
• A Prospective Patient Registry of Patients Exposed to Bedaquiline
• Brief Bactericidal Activity of Anti-Tuberculosis Drugs
• Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
• Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
• A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
• Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
• A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis
• Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
• Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
• Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis
• To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
• Linezolid to Treat Extensively-Drug Resistant Tuberculosis
• Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)
• A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
• TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB
• High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis
• MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
• Metronidazole for Pulmonary Tuberculosis (South Korea)
• Interferon Gamma for Drug Resistant Tuberculosis